Literature DB >> 2287936

Royal Park Multidiagnostic Instrument for Psychosis: Part I. Rationale and review.

P D McGorry1, D L Copolov, B S Singh.   

Abstract

The Royal Park Multidiagnostic Instrument for Psychosis (RPMIP) is a validity-oriented assessment procedure developed for the acute psychotic episode using serial interviews and multiple information sources to construct a data base of clinical information. A number of sets of operational criteria, including 11 definitions of schizophrenia and several concepts of atypical, schizoaffective, and affective psychoses, are simultaneously applied to the data base to produce a diagnostic profile for each patient that can be linked to other variables. This article describes the rationale for the development of the RPMIP and contrasts it with other assessment and diagnostic procedures. A companion article (Part II) presents data on interrater reliability and procedural validity, together with an account of the structure and development of the instrument.

Entities:  

Mesh：

Year:  1990        PMID： 2287936     DOI： 10.1093/schbul/16.3.501

Source DB:  PubMed          Journal:  Schizophr Bull        ISSN： 0586-7614            Impact factor:   9.306


  8 in total

1.  Early intervention in first-episode psychosis--the impact of a community development campaign.

Authors:  Helen Krstev; Steve Carbone; Susy M Harrigan; Christina Curry; Kathryn Elkins; Patrick D McGorry
Journal:  Soc Psychiatry Psychiatr Epidemiol       Date:  2004-09       Impact factor: 4.328

2.  Rates and predictors of 18-months remission in an epidemiological cohort of 661 patients with first-episode psychosis.

Authors:  Philippe Conus; Sue Cotton; Benno G Schimmelmann; Patrick D McGorry; Martin Lambert
Journal:  Soc Psychiatry Psychiatr Epidemiol       Date:  2017-05-05       Impact factor: 4.328

3.  Pretreatment and outcome correlates of sexual and physical trauma in an epidemiological cohort of first-episode psychosis patients.

Authors:  Philippe Conus; Sue Cotton; Benno G Schimmelmann; Patrick D McGorry; Martin Lambert
Journal:  Schizophr Bull       Date:  2009-04-21       Impact factor: 9.306

4.  Alterations in facial expressivity in youth at clinical high-risk for psychosis.

Authors:  Tina Gupta; Claudia M Haase; Gregory P Strauss; Alex S Cohen; Vijay A Mittal
Journal:  J Abnorm Psychol       Date:  2019-03-14

5.  Randomized Controlled Trial of Clozapine and CBT for First-Episode Psychosis with Enduring Positive Symptoms: A Pilot Study.

Authors:  J Edwards; J Cocks; P Burnett; D Maud; L Wong; H P Yuen; S M Harrigan; T Herrman-Doig; B Murphy; D Wade; P D McGorry
Journal:  Schizophr Res Treatment       Date:  2011-03-30

6.  Reduction of Involuntary Admissions in Patients With Severe Psychotic Disorders Treated in the ACCESS Integrated Care Model Including Therapeutic Assertive Community Treatment.

Authors:  Daniel Schöttle; Friederike Ruppelt; Benno G Schimmelmann; Anne Karow; Alexandra Bussopulos; Jürgen Gallinat; Klaus Wiedemann; Daniel Luedecke; Anja Christine Rohenkohl; Christian G Huber; Thomas Bock; Martin Lambert
Journal:  Front Psychiatry       Date:  2019-10-24       Impact factor: 4.157

7.  Divergent effects of first-generation and second-generation antipsychotics on cortical thickness in first-episode psychosis.

Authors:  B R E Ansell; D B Dwyer; S J Wood; E Bora; W J Brewer; T M Proffitt; D Velakoulis; P D McGorry; C Pantelis
Journal:  Psychol Med       Date:  2014-07-31       Impact factor: 7.723

8.  Effectiveness of integrated care including therapeutic assertive community treatment in severe schizophrenia-spectrum and bipolar I disorders: Four-year follow-up of the ACCESS II study.

Authors:  Daniel Schöttle; Benno G Schimmelmann; Friederike Ruppelt; Alexandra Bussopulos; Marietta Frieling; Evangelia Nika; Luise Antonia Nawara; Dietmar Golks; Andrea Kerstan; Matthias Lange; Michael Schödlbauer; Anne Daubmann; Karl Wegscheider; Anja Rohenkohl; Gizem Sarikaya; Mary Sengutta; Daniel Luedecke; Linus Wittmann; Gunda Ohm; Christina Meigel-Schleiff; Jürgen Gallinat; Klaus Wiedemann; Thomas Bock; Anne Karow; Martin Lambert
Journal:  PLoS One       Date:  2018-02-27       Impact factor: 3.240
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.